APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy

Yoshio Tsuboi, Keith Anthony Josephs, Natalie Cookson, Dennis W Dickson

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: To assess demographic and genetic determinants of Alzheimer type pathology in progressive supranuclear palsy (PSP). Methods: From a total of 173 pathologically proven cases of PSP in the Society for PSP Brain Bank, 143 patients (mean age = 74.4 years, ranging from 42 to 98 years) were suitable for genetic and pathologic study. Senile plaques (SPs) and neurofibrillary tangles (NFTs) were counted in five cortical areas, Braak stage was given, and APOE genotype was determined from DNA isolated from frozen brain tissue. The APOE allele frequency in PSP with varying degrees of concomitant Alzheimer type pathology was compared with pure PSP and autopsy controls. The relationship of APOE ε4 to quantitative pathologic measures was also assessed. Results: Most patients with PSP (103 cases) had either minimal or no Alzheimer type pathology (Braak stage III or less), but 14 patients had many SPs (>20 per low power field) and a Braak stage of IV or higher consistent with pathologic criteria for AD, and 26 patients had many diffuse plaques with minimal neurofibrillary degeneration (Braak stage III or less) consistent with pathologic aging. Alzheimer type pathology was more frequent in women and older individuals with PSP, and 19 of the 40 patients with PSP with Alzheimer type pathology carried at least one APOE ε4 allele. The ε4 allele frequency was significantly higher in PSP with AD or pathologic aging than in pure PSP, and APOE ε4 correlated with the average maximal density of both neocortical SPs and NFTs. Conclusion: APOE ε4 is a risk factor for Alzheimer type pathology in PSP. Alzheimer type pathology is an independent process unrelated to PSP in cases with both types of pathologies.

Original languageEnglish (US)
Pages (from-to)240-245
Number of pages6
JournalNeurology
Volume60
Issue number2
StatePublished - Jan 28 2003

Fingerprint

Progressive Supranuclear Palsy
Pathology
Amyloid Plaques
Neurofibrillary Tangles
Gene Frequency
Brain
Autopsy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy. / Tsuboi, Yoshio; Josephs, Keith Anthony; Cookson, Natalie; Dickson, Dennis W.

In: Neurology, Vol. 60, No. 2, 28.01.2003, p. 240-245.

Research output: Contribution to journalArticle

@article{de9b942bdef944b6bffa0b850c63729d,
title = "APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy",
abstract = "Objective: To assess demographic and genetic determinants of Alzheimer type pathology in progressive supranuclear palsy (PSP). Methods: From a total of 173 pathologically proven cases of PSP in the Society for PSP Brain Bank, 143 patients (mean age = 74.4 years, ranging from 42 to 98 years) were suitable for genetic and pathologic study. Senile plaques (SPs) and neurofibrillary tangles (NFTs) were counted in five cortical areas, Braak stage was given, and APOE genotype was determined from DNA isolated from frozen brain tissue. The APOE allele frequency in PSP with varying degrees of concomitant Alzheimer type pathology was compared with pure PSP and autopsy controls. The relationship of APOE ε4 to quantitative pathologic measures was also assessed. Results: Most patients with PSP (103 cases) had either minimal or no Alzheimer type pathology (Braak stage III or less), but 14 patients had many SPs (>20 per low power field) and a Braak stage of IV or higher consistent with pathologic criteria for AD, and 26 patients had many diffuse plaques with minimal neurofibrillary degeneration (Braak stage III or less) consistent with pathologic aging. Alzheimer type pathology was more frequent in women and older individuals with PSP, and 19 of the 40 patients with PSP with Alzheimer type pathology carried at least one APOE ε4 allele. The ε4 allele frequency was significantly higher in PSP with AD or pathologic aging than in pure PSP, and APOE ε4 correlated with the average maximal density of both neocortical SPs and NFTs. Conclusion: APOE ε4 is a risk factor for Alzheimer type pathology in PSP. Alzheimer type pathology is an independent process unrelated to PSP in cases with both types of pathologies.",
author = "Yoshio Tsuboi and Josephs, {Keith Anthony} and Natalie Cookson and Dickson, {Dennis W}",
year = "2003",
month = "1",
day = "28",
language = "English (US)",
volume = "60",
pages = "240--245",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy

AU - Tsuboi, Yoshio

AU - Josephs, Keith Anthony

AU - Cookson, Natalie

AU - Dickson, Dennis W

PY - 2003/1/28

Y1 - 2003/1/28

N2 - Objective: To assess demographic and genetic determinants of Alzheimer type pathology in progressive supranuclear palsy (PSP). Methods: From a total of 173 pathologically proven cases of PSP in the Society for PSP Brain Bank, 143 patients (mean age = 74.4 years, ranging from 42 to 98 years) were suitable for genetic and pathologic study. Senile plaques (SPs) and neurofibrillary tangles (NFTs) were counted in five cortical areas, Braak stage was given, and APOE genotype was determined from DNA isolated from frozen brain tissue. The APOE allele frequency in PSP with varying degrees of concomitant Alzheimer type pathology was compared with pure PSP and autopsy controls. The relationship of APOE ε4 to quantitative pathologic measures was also assessed. Results: Most patients with PSP (103 cases) had either minimal or no Alzheimer type pathology (Braak stage III or less), but 14 patients had many SPs (>20 per low power field) and a Braak stage of IV or higher consistent with pathologic criteria for AD, and 26 patients had many diffuse plaques with minimal neurofibrillary degeneration (Braak stage III or less) consistent with pathologic aging. Alzheimer type pathology was more frequent in women and older individuals with PSP, and 19 of the 40 patients with PSP with Alzheimer type pathology carried at least one APOE ε4 allele. The ε4 allele frequency was significantly higher in PSP with AD or pathologic aging than in pure PSP, and APOE ε4 correlated with the average maximal density of both neocortical SPs and NFTs. Conclusion: APOE ε4 is a risk factor for Alzheimer type pathology in PSP. Alzheimer type pathology is an independent process unrelated to PSP in cases with both types of pathologies.

AB - Objective: To assess demographic and genetic determinants of Alzheimer type pathology in progressive supranuclear palsy (PSP). Methods: From a total of 173 pathologically proven cases of PSP in the Society for PSP Brain Bank, 143 patients (mean age = 74.4 years, ranging from 42 to 98 years) were suitable for genetic and pathologic study. Senile plaques (SPs) and neurofibrillary tangles (NFTs) were counted in five cortical areas, Braak stage was given, and APOE genotype was determined from DNA isolated from frozen brain tissue. The APOE allele frequency in PSP with varying degrees of concomitant Alzheimer type pathology was compared with pure PSP and autopsy controls. The relationship of APOE ε4 to quantitative pathologic measures was also assessed. Results: Most patients with PSP (103 cases) had either minimal or no Alzheimer type pathology (Braak stage III or less), but 14 patients had many SPs (>20 per low power field) and a Braak stage of IV or higher consistent with pathologic criteria for AD, and 26 patients had many diffuse plaques with minimal neurofibrillary degeneration (Braak stage III or less) consistent with pathologic aging. Alzheimer type pathology was more frequent in women and older individuals with PSP, and 19 of the 40 patients with PSP with Alzheimer type pathology carried at least one APOE ε4 allele. The ε4 allele frequency was significantly higher in PSP with AD or pathologic aging than in pure PSP, and APOE ε4 correlated with the average maximal density of both neocortical SPs and NFTs. Conclusion: APOE ε4 is a risk factor for Alzheimer type pathology in PSP. Alzheimer type pathology is an independent process unrelated to PSP in cases with both types of pathologies.

UR - http://www.scopus.com/inward/record.url?scp=0037469193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037469193&partnerID=8YFLogxK

M3 - Article

C2 - 12552038

AN - SCOPUS:0037469193

VL - 60

SP - 240

EP - 245

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -